Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PTN vs CLYM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CLYM Captures Overall Composite Edge (45.7 HOLD vs 31.5 SELL), While PTN Leads 3–2 on Growth & Valuation Pillars

CLYM Overall Winner 6-Pillar Tally: PTN 3 – 2 CLYM (1 Tie) Matrix Metrics: PTN 3 – 7 CLYM

As of Nov 16, 2026, Climb Bio, Inc. (CLYM) captures the overall head-to-head institutional edge over Palatin Technologies, Inc. (PTN) on higher Unified Composite conviction (45.7/100 HOLD vs. 31.5/100 SELL) after splitting the core matrix 7–3 (led by Growth & Scale, Profitability & Quality), while PTN wins 3–2 across the 6-pillar growth and valuation breakdown. PTN trades at $6.12 (42.9x Forward P/E, -65.7% operating margin) versus CLYM at $9.94 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: CLYM earns the overall head-to-head edge with a stronger Unified Composite Score (45.7/100 HOLD vs. PTN 31.5/100 SELL) and 1.50β · 114% Vol risk profile, whereas PTN leads top-line expansion (-80.1% YoY revenue growth, 1.62x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: PTN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.9); meanwhile CLYM trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PTN vs CLYM
PTN US Equity
Palatin Technologies, Inc.
Pharmaceutical Preparations
$6.12
-1.69% 1D
Market Cap $11.1M
TTM Revenue $13M
Forward P/E 42.9x
Beta / 30D Vol 0.87β · 106% Vol
Unified Composite Score
31.5 / 100 SELL
Tech 15.0 Fund 30.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.5%), weak momentum, RSI 45
RSI-14: 44.9 · SMA20: $5.72 · SMA50: $8.07
CLYM NASDAQ Head-to-Head Winner
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$9.94
-4.05% 1D
Market Cap $608.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.50β · 114% Vol
Unified Composite Score
45.7 / 100 HOLD
Tech 41.0 Fund 47.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 45.2 · SMA20: $10.28 · SMA50: $11.47

6-Pillar Scorecard Institutional Category Breakdown (PTN 3 – 2 CLYM)

Columns: Metric · PTN · CLYM
1. Valuation Multiples PTN
Forward P/E 42.9x N/M
Trailing P/E 42.9x N/M
PEG Ratio 1.62x N/M
EV / Revenue 0.1x N/M
2. Growth & Scale CLYM
Revenue Growth (YoY) -80.1% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $13M N/A
Market Cap $11.1M $608.5M
3. Profitability & Quality CLYM
Gross Margin 6.2% N/A
Operating Margin -65.7% 0.0%
Net Profit Margin -63.5% 0.0%
Return on Equity (ROE) -877.5% -29.3%
4. Balance Sheet & Cash Flow PTN
Cash Generation (TTM) -$15M N/A
Cash Flow Margin -113.6% N/A
Net Cash / Leverage $9.9M Net Cash $3.95 Book/Sh · -29.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat PTN
OpEx & R&D Intensity 71.9% of Rev ($9.5M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PTN (3) vs CLYM (7)
Institutional Metric PTN CLYM Criterion Row Edge
Market Capitalization
Scale
$11.1M $608.5M Larger Scale CLYM
Trailing P/E Ratio
Valuation
42.9x N/M Lower Multiple PTN
Forward P/E Ratio
Valuation
42.9x N/M Lower Multiple PTN
Revenue Growth (YoY)
Growth
-80.1% +0.0% Higher Growth CLYM
Operating Margin (TTM)
Profitability
-65.7% 0.0% Higher Margin CLYM
Net Profit Margin
Profitability
-63.5% 0.0% Higher Margin CLYM
Return on Equity (ROE)
Capital Efficiency
-877.5% -29.3% Higher ROE CLYM
52-Week Range Position
Momentum
6% ($5–$31) 50% ($2–$18) Stronger Trend CLYM
Beta / 30D Volatility
Risk Regime
0.87β · 106% Vol 1.50β · 114% Vol Lower Realized Risk PTN
Unified Institutional Score
Composite Signal
31.5 / 100 (SELL) 45.7 / 100 (HOLD) Higher Composite CLYM
Trailing 12M Revenue (USD)
Operating Scale
$13M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
6.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.62x PEG · 0.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$15M ($9.9M Net Cash) N/A ($3.95 Book/Sh · -29.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PTN +0.52 pp
PTN: +1.74% · CLYM: +1.22%
3M Horizon PTN +1.12 pp
PTN: -41.72% · CLYM: -42.84%
6M Horizon CLYM +60.42 pp
PTN: -59.81% · CLYM: +0.61%
1Y Horizon CLYM +474.84 pp
PTN: -43.29% · CLYM: +431.55%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PTN vs CLYM. Trailing 12-month operating profitability (PTN -65.7% vs CLYM 0.0%) and valuation multiples (PTN 42.9x vs CLYM N/M Forward P/E) are benchmarked directly in Pillar 4 below.

PTN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$13M
Gross Margin6.2%
Op. Margin-65.7%
ROE / Fwd P/E-877.5% · 42.9x
CLYM ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-29.3% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PTN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PTN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CLYM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CLYM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PTN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $11.1M market capitalization and -65.7% operating margin.
OpEx & R&D Reinvestment 71.9% of Rev ($9.5M)
90D Engineering Disclosures 0 Published
CLYM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $608.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PTN vs CLYM Key Questions & Quantitative Answers

As of Nov 16, 2026, Climb Bio, Inc. (CLYM) captures the overall head-to-head institutional edge over Palatin Technologies, Inc. (PTN) on higher Unified Composite conviction (45.7/100 HOLD vs. 31.5/100 SELL) after splitting the core matrix 7–3 (led by Growth & Scale, Profitability & Quality), while PTN wins 3–2 across the 6-pillar growth and valuation breakdown. PTN trades at $6.12 (42.9x Forward P/E, -65.7% operating margin) versus CLYM at $9.94 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: CLYM earns the overall head-to-head edge with a stronger Unified Composite Score (45.7/100 HOLD vs. PTN 31.5/100 SELL) and 1.50β · 114% Vol risk profile, whereas PTN leads top-line expansion (-80.1% YoY revenue growth, 1.62x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: PTN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.9); meanwhile CLYM trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CLYM leads the Growth & Scale pillar: PTN posts -80.1% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (6.2% gross margin, -65.7% operating margin), compared with CLYM at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, PTN generates $13M in USD-normalized revenue versus N/A for CLYM. In operating R&D and SG&A reinvestment, PTN deploys 71.9% of Rev ($9.5M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CLYM.

PTN screens cheaper on headline valuation multiples. PTN trades at 42.9x Forward P/E, 42.9x Trailing P/E, 1.62x PEG, and 0.1x EV/Revenue (-113.6% FCF margin), whereas CLYM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PTN (-877.5% ROE) versus CLYM (-29.3% ROE) capital efficiency.

In options market volatility and institutional positioning, PTN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.87β · 106% Vol realized risk). By comparison, CLYM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.50β · 114% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.